Skip to content
Clinical Trials – home
Therapeutic area

Psychiatric disorders – page 40

  • 546 clinical trials
  • 252 recruiting
  • 147 conditions
  • 26 countries

Conditions in this area

147 conditions with trials, the busiest first

Clinical trials in Psychiatric disorders

546 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

546 clinical trials

Sleep disorder+1

Not recruiting

Study on Elinzanetant for Treating Sleep Disturbances in Menopausal Women

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Elinzanetant
  • Sponsor:Bayer AG

Study of RO7269162 in people at risk for or with early-stage Alzheimer's Disease: Effects on brain amyloid buildup

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Florbetaben (18F)
  • Sponsor:F. Hoffmann-La Roche AG

Study on the Effectiveness and Safety of Dexamfetamine Sulfate for Adults with ADHD

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Dexamfetamine Sulfate
  • Sponsor:MEDICE Arzneimittel Puetter GmbH & Co. KG
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Emraclidine
  • Sponsor:Cerevel Therapeutics LLC

Study on the Long-term Effects of Methylone for Treating PTSD in Patients

InvestigationalNo placebo
Countries:IrelandIreland
  • Participants:18–64 years · 65+ years
  • Substances:Methylone
  • Sponsor:Transcend Therapeutics Inc.

Phenylketonuria

Not recruiting

Study Comparing Sepiapterin and Sapropterin for Treating Phenylketonuria in Patients Aged 2 Years and Older

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:(S)-2-Amino-6-(2-Hydroxypropanoyl)-7,8-Dihydropteridin-4(3H)-One
  • Sponsor:PTC Therapeutics Inc.

Study on the Effects of AR1001 (Mirodenafil Dihydrochloride) for Patients with Early Alzheimer's Disease

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Mirodenafil Dihydrochloride
  • Sponsor:Aribio Co. Ltd.

Study on AVP-786 for Treating Agitation in Alzheimer's Dementia Patients

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Quinidine Sulfate
  • Sponsor:Otsuka Pharmaceutical Development & Commercialization Inc.

Study Comparing Human Normal Immunoglobulin and Placebo for Children with Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS)

Registered drug
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Human Normal Immunoglobulin
  • Sponsor:Octapharma Pharmazeutika Produktionsgesellschaft mbH

Fragile X syndrome

Not recruiting

Study on Long-Term Safety of ZYN002 Gel for Children, Adolescents, and Young Adults with Fragile X Syndrome

InvestigationalNo placebo
Countries:IrelandIreland
  • Participants:0–17 years · 18–64 years
  • Substances:Cannabidiol
  • Sponsor:Harmony Biosciences Management Inc.

Major depression

Not recruiting

Study on the Effectiveness and Safety of REL-1017 for Patients with Major Depression Who Have Not Responded to Current Treatment

Investigational
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Dextromethadone Hydrochloride
  • Sponsor:Mggm LLC

Cognitive disorder

Not recruiting

Study on the Effectiveness and Safety of Oral Midazolam for Elderly Patients with Severe Neurocognitive Disorders and Care Resistance

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Midazolam
  • Sponsor:Centre Hospitalier Universitaire Grenoble Alpes

Substances studied in this area

The therapies tested most often in Psychiatric disorders trials.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.